Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 13,684 Shares

May 22, 2026 by InsiderTrades.com

Key Points

Royalty Pharma EVP Marshall Urist sold 13,684 shares on May 20 at an average price of $52.75, totaling about $721,831. The sale was made under a pre-arranged Rule 10b5-1 trading plan and reduced his ownership by 42.92%.
The stock has been trading near its 52-week high, opening at $53.55 versus a 1-year high of $53.59. Royalty Pharma also has a market cap of about $30.84 billion and a beta of 0.40.
Royalty Pharma reported solid first-quarter results and continues to attract bullish analyst support. It beat EPS estimates at $1.30 per share, and several firms recently raised price targets or reaffirmed buy ratings, with a consensus target of $53.71.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total value of $721,831.00. Following the completion of the transaction, the executive vice president directly owned 18,197 shares in the company, valued at $959,891.75. This represents a 42.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Marshall Urist also recently made the following trade(s):

On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total value of $726,073.04.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $53.55 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market capitalization of $30.84 billion, a P/E ratio of 36.43, a P/E/G ratio of 1.46 and a beta of 0.40. The business's 50-day simple moving average is $48.87 and its 200-day simple moving average is $43.84. Royalty Pharma PLC has a 1-year low of $32.15 and a 1-year high of $53.59.

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. The business had revenue of $631.00 million for the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Equities analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma's payout ratio is presently 63.95%.

Hedge Funds Weigh In On Royalty Pharma

4 Healthcare Stocks With Massive Gains—and More to Come

Institutional investors have recently made changes to their positions in the business. LM Advisors LLC acquired a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $26,000. Blue Trust Inc. raised its position in shares of Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 437 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new position in shares of Royalty Pharma in the 4th quarter valued at approximately $30,000. Private Trust Co. NA raised its position in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on RPRX. UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, April 21st. TD Cowen reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, February 27th. Morgan Stanley boosted their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. The Goldman Sachs Group reissued a "buy" rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Finally, JPMorgan Chase & Co. boosted their price target on Royalty Pharma from $50.00 to $58.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $53.71.

Check Out Our Latest Stock Report on Royalty Pharma

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.